CSF1 overexpression has pleiotropic effects on microglia in vivo
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Macrophage colony stimulating factor (CSF1) is a cytokine that is upregulated in several diseases of the central nervous system (CNS). To examine the effects of CSF1 overexpression on microglia, transgenic mice that overexpress CSF1 in the glial fibrillary acidic protein (GFAP) compartment were generated. CSF1 overexpressing mice have increased microglial proliferation and increased microglial numbers compared with controls. Treatment with PLX3397, a small molecule inhibitor of the CSF1 receptor CSF1R and related kinases, decreases microglial numbers by promoting microglial apoptosis in both CSF1 overexpressing and control mice. Microglia in CSF1 overexpressing mice exhibit gene expression profiles indicating that they are not basally M1 or M2 polarized, but they do have defects in inducing expression of certain genes in response to the inflammatory stimulus lipopolysaccharide. These results indicate that the CSF1 overexpression observed in CNS pathologies likely has pleiotropic influences on microglia. Furthermore, small molecule inhibition of CSF1R has the potential to reverse CSF1‐driven microglial accumulation that is frequently observed in CNS pathologies, but can also promote apoptosis of normal microglia. GLIA 2014;62:1955–1967
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 3×
“GW2580 and BLZ945 are reported to be highly selective CSF1R inhibitors (Conway et al., 2005; Pyonteck et al., 2013), while PLX3397 inhibits CSF1R (in vitro IC50 20 nM), cKIT (in vitro IC50 10 nM) and to a lesser extent FLT3 (in vitro IC50 160 nM; DeNardo et al., 2011).”
BackgroundElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968 · cited 4×
“Elmore et al. (2014) also found no differences in expression of neuronal or oligodendrocyte markers following PLX3397 treatment.”
BackgroundMethodResultInfluentialDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594 · cited 1×
“In support of this, a similar approach was utilized to examine the impact of CSF1 overexpression on breast cancer progression using a tTA line that expresses in salivary and mammary glands (Lin et al., 2001).”
MethodWang, Y., Szretter, K. J., Vermi, W., Gilfillan, S., Rossini, C., Cella, M., Barrow, A. D., Diamond, M. S., & Colonna, M. (2012) · Nature Immunology · doi:10.1038/ni.2360 · Cited by 1,011 · cited 1×
“IL-34 is a second ligand for CSF1R and Il-34 deficient mice also have reduced microglial numbers with the reduction in Il-34 null mice being potentially more severe than in Csf1 deficient mice (Greter et al., 2012; Kondo and Duncan, 2009; Wang et al., 2012).”
BackgroundSelective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain
Lalancette-Hébert, M., Gowing, G., Simard, A., Weng, Y. C., & Kriz, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5360-06.2007 · Cited by 874
CSF-1 regulation of the wandering macrophage: complexity in action
Pixley, F. J., & Stanley, E. R. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.016 · Cited by 807
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738 · cited 2×
“PLX3397 is also currently in clinical trials for several cancer types including glioblastoma (clinicaltrials.gov), which are known to express high levels of CSF1 (Bender et al., 2010; Komohara et al., 2008).”
BackgroundErblich, B., Zhu, L., Etgen, A. M., Dobrenis, K., & Pollard, J. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026317 · Cited by 649 · cited 1×
“Csf1r deficient mice have severe reductions in microglia due to a disruption in microglial development (Erblich et al., 2011; Ginhoux et al., 2010).”
BackgroundGreter, M., Lelios, I., Pelczar, P., Hoeffel, G., Price, J., Leboeuf, M., Kündig, T. M., Frei, K., Ginhoux, F., Merad, M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.11.001 · Cited by 630 · cited 1×
“IL-34 is a second ligand for CSF1R and Il-34 deficient mice also have reduced microglial numbers with the reduction in Il-34 null mice being potentially more severe than in Csf1 deficient mice (Greter et al., 2012; Kondo and Duncan, 2009; Wang et al., 2012).”
BackgroundFleetwood, A. J., Lawrence, T., Hamilton, J. A., & Cook, A. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5245 · Cited by 607
Regulation of Microglial Proliferation during Chronic Neurodegeneration
Gómez-Nicola, D., Fransen, N. L., Suzzi, S., & Perry, V. H. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4440-12.2013 · Cited by 407
Intracellular signaling in M‐CSF‐induced microglia activation: Role of Iba1
Imai, Y., & Kohsaka, S. (2002) · Glia · doi:10.1002/glia.10149 · Cited by 359 · cited 1×
“Increased levels of CSF1, increased microglia and microglial activation are found in many different CNS pathologies including tumors, neurodegenerative diseases, and injury (Charles et al., 2012; El Khoury and Luster, 2008; Imai and Kohsaka, 2002; Loane and Byrnes, 2010).”
BackgroundLuo, J., Elwood, F., Britschgi, M., Villeda, S., Zhang, H., Ding, Z., Zhu, L., Alabsi, H., Getachew, R., Narasimhan, R., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20120412 · Cited by 262
Microglia in the developing brain: a potential target with lifetime effects
Harry, G. J., & Kraft, A. D. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.01.012 · Cited by 250
Boissonneault, V., Filali, M., Lessard, M., Relton, J., Wong, G., & Rivest, S. (2008) · Brain · doi:10.1093/brain/awn331 · Cited by 221 · cited 8×
“Pharmacological Inhibition of CSF1R with PLX3397 Promotes Microglial Apoptosis and Reverses Microglial Phenotypes in CSF1 Overexpressing Mice PLX3397 is a small molecule inhibitor of CSF1R and related kinases (DeNardo et al., 2011) that is able to cross the blood brain barrier (BBB; Coniglio et al., 2012).”
BackgroundMethodInfluentialGM‐CSF promotes proliferation of human fetal and adult microglia in primary cultures
Lee, S. C., Liu, W., Brosnan, C. F., & Dickson, D. W. (1994) · Glia · doi:10.1002/glia.440120407 · Cited by 209 · cited 1×
“In vitro, most studies have concluded that CSF1 acts as a mitogen for fetal, neonatal and adult microglia (Giulian and Ingeman, 1988; Lee et al., 1993; Lee et al., 1994; Liu et al., 2011; Smith et al., 2013; Yamamoto et al., 2010).”
BackgroundMechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications
Khoury, J. E., & Luster, A. D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.08.004 · Cited by 171
Smith, A. M., Gibbons, H. M., Oldfield, R. L., Bergin, P. M., Mee, E. W., Curtis, M. A., Faull, R. L. M., & Dragunow, M. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-85 · Cited by 107 · cited 1×
“In vitro, most studies have concluded that CSF1 acts as a mitogen for fetal, neonatal and adult microglia (Giulian and Ingeman, 1988; Lee et al., 1993; Lee et al., 1994; Liu et al., 2011; Smith et al., 2013; Yamamoto et al., 2010).”
BackgroundGowing, G., Lalancette-Hébert, M., Audet, J.-N., Dequen, F., & Julien, J.-P. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.021 · Cited by 53
Bowerman, M., Vincent, T., Scamps, F., Perrin, F. E., Camu, W., & Raoul, C. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00214 · Cited by 46
Cited by
Walker, D. G., & Lue, L.-F. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0139-9 · Cited by 562
“Recent findings suggest that macrophage colony-stimulating factortreated microglia have neither an M1 or M2a polarization state [48], although other works have classified CSF-1R signaling as similar to M2a activation [10].”
BackgroundEmerging Roles for CSF-1 Receptor and its Ligands in the Nervous System
Chitu, V., Gokhan, Ş., Nandi, S., Mehler, M. F., & Stanley, E. R. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.03.005 · Cited by 362
Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352
Nikodemova, M., Kimyon, R. S., De, I., Small, A. L., Collier, L. S., & Watters, J. J. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.11.018 · Cited by 192
“5 times more microglia in the adult CNS (P42) compared to littermate controls (De et al., 2014); (Fig.”
BackgroundMethodInfluentialAo, J.-Y., Zhu, X.-D., Chai, Z.-T., Cai, H., Zhang, Y.-Y., Zhang, K.-Z., Kong, L.-Q., Zhang, N., Ye, B.-G., Ma, D.-N., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0866 · Cited by 171
“competitive inhibitor with high specificity for CSF-1R tyrosine kinase, has been tested in several studies, with promising therapeutic results (26-33).”
Background
Metadata
- Authors
- De, I., Nikodemova, M., Steffen, M. D., Sokn, E., Maklakova, V. I., Watters, J. J., & Collier, L. S.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2014-07-05
- Volume
- 62
- Issue
- 12
- Pages
- 1955-1967
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2171662375
- Cited by
- 79
- References
- 22
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.